Sami Rahman

Experience

1. Manager, Market Research, Respiratory

   Insmed Incorporated

   Mar 2025 — Present · New York, NY, US

   Market Research, Insights & Analytics | Commercial EffectivenessTherapeutic Areas: Respiratory/Pulmonary – NCFB and MAC-LDBRINSUPRI ™ (brensocatib) is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) adult and pediatric patients 12 years of age and older. As a targeted treatment, BRINSUPRI is a novel, oral, selective, and reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates neutrophil serine proteases (NSPs), drivers of bronchiectasis pathophysiology and chronic airway inflammation. By inhibiting DPP1, brensocatib blocks NSPs - key mediators of both inflammation and lung damage in neutrophil-mediated diseases.ARIKAYCE® (amikacin liposome inhalation suspension) is indicated for the treatment of refractory mycobacterium avium complex (MAC) lung disease, a type of nontuberculous mycobacteria (NTM). ARIKAYCE is an aminoglycoside antibacterial for oral inhalation use for MAC-LD patients who have limited or no alternative treatment options and as part of a combination, multidrug antibacterial regimen on top of existing background therapy.

Education

• Upper Saint Clair High School

  High School Diploma

  2008 — 2012

• Georgetown University

  Master’s Degree

  2016 — 2017

• Georgetown University

  Bachelor of Science (B.S.)

  2012 — 2016

Skills

• Writing
• Public Policy
• Healthcare Management
• Creative Writing
• Microsoft Office
• Powerpoint
• Biotechnology
• Health Economics
• Creative Problem Solving
• Equity Research
• Microsoft Excel
• Acting
• Policy Analysis
• Project Coordination
• Health Policy
• Data Analytics
• Comparative Literature
• Microsoft Powerpoint
• Business Development
• Market Research
• Research